Legend Biotech (LEGN) closed at $19.13 on Aug 4, 2026, up 0.6% on the day. The stock is down 31.8% over the past month, down 27.8% over three months, down 12.0% year to date and down 50.7% over the past year. It trades 49.0% below its 52-week high of $37.50 and 17.8% above its 52-week low of $16.24. The close sits below its 50-day moving average ($27.59) and below its 200-day moving average ($24.39).
LEGN is scheduled to report earnings on Nov 10, 2026, before market open.
Legend Biotech is scheduled to report on Nov 10, 2026, before market open.
No — the Aug 4, 2026 close of $19.13 is 21.6% below the 200-day average of $24.39.
LEGN closed 49.0% below its 52-week high of $37.50.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
